HER2 has a well-known driver role in the carcinogenesis of breast cancer [3]; it is overexpressed in around 10–20% of breast tumors, and it is associated with aggressive behavior, high recurrence rates, and increased mortality [2,4] in both invasive and in situ ductal carcinoma [5]. Here, ERBB2 is linked to breast carcinoma.